LONDON--AstraZeneca PLC (AZN.LN) said Friday has sold its rights outside the U.S. for nasal spray Rhincourt Aqua to Johnson & Johnson (JNJ) affiliate Cilag GmbH International for $330 million.

The British drugs company said the deal should be finalized by the end of this year.

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

October 07, 2016 02:45 ET (06:45 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Astrazeneca Charts.